Quanterix Corporation (QTRX)

$17.02

+0.1

(+0.59%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Quanterix Corporation

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 30.83M → 31.54M (in $), with an average increase of 2.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -6.06M → -12.40M (in $), with an average decrease of 43.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 40.3% return, outperforming this stock by 47.7%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.1% return, outperforming this stock by 135.6%

Performance

  • $16.67
    $17.67
    $17.02
    downward going graph

    2.06%

    Downside

    Day's Volatility :5.66%

    Upside

    3.68%

    downward going graph
  • $12.25
    $29.70
    $17.02
    downward going graph

    28.03%

    Downside

    52 Weeks Volatility :58.75%

    Upside

    42.69%

    downward going graph

Returns

PeriodQuanterix CorporationSector (Health Care)Index (Russel 2000)
3 Months
-27.39%
-0.8%
0.0%
6 Months
-22.85%
10.5%
0.0%
1 Year
-7.45%
6.4%
2.9%
3 Years
-67.46%
14.6%
-21.3%

Highlights

Market Capitalization
596.3M
Book Value
$9.13
Earnings Per Share (EPS)
-0.86
Wall Street Target Price
30.8
Profit Margin
-26.42%
Operating Margin TTM
-36.98%
Return On Assets TTM
-6.47%
Return On Equity TTM
-9.16%
Revenue TTM
122.4M
Revenue Per Share TTM
3.26
Quarterly Revenue Growth YOY
22.2%
Gross Profit TTM
46.8M
EBITDA
-38.1M
Diluted Eps TTM
-0.86
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.0
EPS Estimate Next Year
-0.89
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Quanterix Corporation(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
6
Hold
2
2
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 80.96%

Current $17.02
Target $30.80

Company Financials

FY18Y/Y Change
Revenue
37.6M
↑ 64.52%
Net Income
-31.0M
↑ 14.9%
Net Profit Margin
-82.5%
↑ 35.62%
FY19Y/Y Change
Revenue
56.7M
↑ 50.76%
Net Income
-40.8M
↑ 31.41%
Net Profit Margin
-71.91%
↑ 10.59%
FY20Y/Y Change
Revenue
86.4M
↑ 52.25%
Net Income
-31.5M
↓ 22.71%
Net Profit Margin
-36.5%
↑ 35.41%
FY21Y/Y Change
Revenue
110.6M
↑ 27.99%
Net Income
-57.7M
↑ 82.96%
Net Profit Margin
-52.18%
↓ 15.68%
FY22Y/Y Change
Revenue
105.0M
↓ 5.07%
Net Income
-96.7M
↑ 67.63%
Net Profit Margin
-92.14%
↓ 39.96%
FY23Y/Y Change
Revenue
121.1M
↑ 15.42%
Net Income
-32.3M
↓ 66.56%
Net Profit Margin
-26.69%
↑ 65.45%
Q3 FY22Q/Q Change
Revenue
26.4M
↑ 12.55%
Net Income
-35.1M
↑ 40.81%
Net Profit Margin
-133.0%
↓ 26.69%
Q4 FY22Q/Q Change
Revenue
25.6M
↓ 2.86%
Net Income
-18.6M
↓ 46.95%
Net Profit Margin
-72.63%
↑ 60.37%
Q1 FY23Q/Q Change
Revenue
28.2M
↑ 10.24%
Net Income
-6.1M
↓ 67.19%
Net Profit Margin
-21.62%
↑ 51.01%
Q2 FY23Q/Q Change
Revenue
30.9M
↑ 9.35%
Net Income
-6.1M
↓ 0.64%
Net Profit Margin
-19.64%
↑ 1.98%
Q3 FY23Q/Q Change
Revenue
30.8M
↓ 0.12%
Net Income
-7.8M
↑ 27.94%
Net Profit Margin
-25.16%
↓ 5.52%
Q4 FY23Q/Q Change
Revenue
31.5M
↑ 2.32%
Net Income
-12.4M
↑ 59.95%
Net Profit Margin
-39.33%
↓ 14.17%
FY18Y/Y Change
Total Assets
67.6M
↓ 26.31%
Total Liabilities
26.1M
↑ 0.61%
FY19Y/Y Change
Total Assets
170.0M
↑ 151.3%
Total Liabilities
41.3M
↑ 58.38%
FY20Y/Y Change
Total Assets
271.0M
↑ 59.48%
Total Liabilities
64.9M
↑ 57.22%
FY21Y/Y Change
Total Assets
501.5M
↑ 85.03%
Total Liabilities
60.6M
↓ 6.69%
FY22Y/Y Change
Total Assets
434.2M
↓ 13.42%
Total Liabilities
75.3M
↑ 24.24%
FY23Y/Y Change
Total Assets
425.0M
↓ 2.12%
Total Liabilities
78.1M
↑ 3.75%
Q3 FY22Q/Q Change
Total Assets
446.7M
↓ 8.58%
Total Liabilities
73.9M
↓ 11.09%
Q4 FY22Q/Q Change
Total Assets
434.2M
↓ 2.8%
Total Liabilities
75.3M
↑ 1.8%
Q1 FY23Q/Q Change
Total Assets
427.3M
↓ 1.59%
Total Liabilities
70.0M
↓ 7.01%
Q2 FY23Q/Q Change
Total Assets
429.2M
↑ 0.44%
Total Liabilities
73.9M
↑ 5.53%
Q3 FY23Q/Q Change
Total Assets
429.0M
↓ 0.04%
Total Liabilities
75.7M
↑ 2.49%
Q4 FY23Q/Q Change
Total Assets
425.0M
↓ 0.94%
Total Liabilities
78.1M
↑ 3.16%
FY18Y/Y Change
Operating Cash Flow
-28.7M
↑ 29.92%
Investing Cash Flow
-5.5M
↑ 381.8%
Financing Cash Flow
-78.0K
↓ 100.11%
FY19Y/Y Change
Operating Cash Flow
-26.2M
↓ 8.82%
Investing Cash Flow
-25.4M
↑ 365.27%
Financing Cash Flow
116.2M
↓ 149070.51%
FY20Y/Y Change
Operating Cash Flow
-23.4M
↓ 10.78%
Investing Cash Flow
-626.0K
↓ 97.53%
Financing Cash Flow
96.2M
↓ 17.18%
FY21Y/Y Change
Operating Cash Flow
-47.9M
↑ 105.04%
Investing Cash Flow
-6.3M
↑ 912.46%
Financing Cash Flow
270.8M
↑ 181.39%
FY22Y/Y Change
Operating Cash Flow
-48.3M
↑ 0.76%
Investing Cash Flow
-11.2M
↑ 76.81%
Financing Cash Flow
2.3M
↓ 99.15%
Q3 FY22Q/Q Change
Operating Cash Flow
-14.5M
↑ 83.21%
Investing Cash Flow
-3.7M
↓ 27.33%
Financing Cash Flow
407.0K
↑ 92.89%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.1M
↓ 71.88%
Investing Cash Flow
-1.6M
↓ 56.62%
Financing Cash Flow
714.0K
↑ 75.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-9.5M
↑ 132.32%
Investing Cash Flow
-136.0K
↓ 91.47%
Financing Cash Flow
551.0K
↓ 22.83%
Q2 FY23Q/Q Change
Operating Cash Flow
633.0K
↓ 106.66%
Investing Cash Flow
-648.0K
↑ 376.47%
Financing Cash Flow
139.0K
↓ 74.77%

Technicals Summary

Sell

Neutral

Buy

Quanterix Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quanterix Corporation
Quanterix Corporation
-21.2%
-22.85%
-7.45%
-67.46%
-26.16%
Stryker Corporation
Stryker Corporation
-5.45%
18.64%
15.4%
28.51%
71.95%
Boston Scientific Corp.
Boston Scientific Corp.
7.53%
37.95%
40.26%
68.13%
94.94%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-6.52%
27.05%
-3.01%
-8.64%
39.76%
Abbott Laboratories
Abbott Laboratories
-3.82%
11.47%
-4.47%
-9.9%
33.93%
Medtronic Plc
Medtronic Plc
-2.66%
11.26%
-8.49%
-36.43%
-9.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quanterix Corporation
Quanterix Corporation
NA
NA
NA
-1.0
-0.09
-0.06
NA
9.13
Stryker Corporation
Stryker Corporation
40.83
40.83
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
68.14
68.14
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.58
37.58
5.19
2.75
0.21
0.12
NA
11.83
Abbott Laboratories
Abbott Laboratories
33.3
33.3
5.99
4.6
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.52
25.52
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quanterix Corporation
Quanterix Corporation
Buy
$596.3M
-26.16%
NA
-26.42%
Stryker Corporation
Stryker Corporation
Buy
$128.2B
71.95%
40.83
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$107.2B
94.94%
68.14
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.0B
39.76%
37.58
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$185.5B
33.93%
33.3
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-9.38%
25.52
13.0%

Institutional Holdings

  • BlackRock Inc

    8.38%

  • Millennium Management LLC

    5.80%

  • Vanguard Group Inc

    5.40%

  • Lord, Abbett & Co LLC

    3.76%

  • Portolan Capital Management, LLC

    3.41%

  • Gilder Gagnon Howe & CO LLC

    3.16%

Corporate Announcements

  • Quanterix Corporation Earnings

    Quanterix Corporation’s price-to-earnings ratio stands at None

    Read More

Company Information

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).

Organization
Quanterix Corporation
Employees
441
CEO
Dr. Masoud Toloue Ph.D.
Industry
Health Technology

Discover More

FAQs